| 000 | 01871 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250515230320.0 | ||
| 264 | 0 | _c20101020 | |
| 008 | 201010s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.25278 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAbramson, Jeremy S | |
| 245 | 0 | 0 |
_aIntravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. _h[electronic resource] |
| 260 |
_bCancer _cSep 2010 |
||
| 300 |
_a4283-90 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xanalysis |
| 650 | 0 | 4 |
_aCentral Nervous System Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xanalysis |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDoxorubicin _xanalysis |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 |
_aLymphoma, Large B-Cell, Diffuse _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrednisone _xanalysis |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aVincristine _xanalysis |
| 700 | 1 | _aHellmann, Matthew | |
| 700 | 1 | _aBarnes, Jeffrey A | |
| 700 | 1 | _aHammerman, Peter | |
| 700 | 1 | _aToomey, Christiana | |
| 700 | 1 | _aTakvorian, Tak | |
| 700 | 1 | _aMuzikansky, Alona | |
| 700 | 1 | _aHochberg, Ephraim P | |
| 773 | 0 |
_tCancer _gvol. 116 _gno. 18 _gp. 4283-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.25278 _zAvailable from publisher's website |
| 999 |
_c19912863 _d19912863 |
||